ZLAB Sep 2024 22.500 put
| Previous Close | 5.51 |
| Open | 4.80 |
| Bid | 3.60 |
| Ask | 8.00 |
| Strike | 22.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 4.80 - 5.51 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 22 |
GuruFocus.comInsider Selling: Chairperson & CEO Ying Du Sells Shares of Zai Lab Ltd (ZLAB)
On June 26, 2024, Ying Du, Chairperson & CEO of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 23,939 shares of the company, according to the SEC Filing. Zai Lab Ltd (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for cancer, autoimmune, and infectious diseases. Over the past year, Ying Du has sold a total of 38,106 shares of Zai Lab Ltd and has not made any purchases of the stock.
Simply Wall St.Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
Key Insights Zai Lab's Annual General Meeting to take place on 18th of June CEO Samantha Du's total compensation...
Business WireZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
SHANGHAI & CAMBRIDGE, Mass., June 11, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume respons
